Florence Dalenc

A Causal Multi-modal AI Model Stratifies Residual Risk and Identifies Candidates for Treatment Escalation in Node-Positive HR+/HER2- Early Breast Cancer

Thomas Bachelot, Sylvie Chabaud, Jérôme Lemonnier, Paul H. Cottu et autres

PURPOSE Prognostic biomarkers that estimate residual recurrence risk after standard adjuvant therapy to guide further treatment escalation are an unmet clinical need. This study used Ataraxis Breast CTX, a causal multi-modal AI model integrating clinical variables and histopathology, to stratify residual risk …

fr, us (code pays fourni par la source)

Supplementary Data1 from Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial

Komal L. Jhaveri, Hope S. Rugo, Javier Cortés, Mafalda Oliveira et autres

Figure S1, Figure S2, Figure S3, Table 1 References.

Data from Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial

Komal L. Jhaveri, Hope S. Rugo, Javier Cortés, Mafalda Oliveira et autres

Abstract Purpose: The phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) pathway is frequently activated in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, with loss of phosphatase and tensin homolog (PTEN) activity contributing to this activation. Capivasertib is a …

Prediction of benefit from docetaxel chemotherapy for HR-positive breast cancer in the PACS-01 trial

Frederique Madeleine Penault-Llorca, Amélie Lusque, Thomas Filleron, Kevin Tran et autres

Background Adjuvant chemotherapy for hormone receptor–positive (HR+) breast cancer relies on taxanes, but existing tests do not identify which patients benefit from them. The SET ER/PR index, a measure of endocrine-related transcriptional activity in HR+ tumors, recently predicted benefit from paclitaxel when …

fr, us (code pays fourni par la source)

A deep-learning model based on histological images predicts survival and pathological response to neoadjuvant chemotherapy and chemoimmunotherapy in breast cancer

François Bertucci, Gwénaël Lumet, Mathieu Delattre, Pascal Finetti et autres

fr, it, qa (code pays fourni par la source)

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

Nicholas C. Turner, Erica L. Mayer, Yeon Hee Park, Wolfgang Janni et autres

gb, us, kr, de, it, jp, ca, pl, es, tr, il, tw, fr, nl (code pays fourni par la source)

Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort

Marie Alexandre, Eva Teruel, Florence Dalenc, Thibaut De La Motte Rouge et autres

BACKGROUND: Breast cancers expressing low (1-9%) immunohistochemistry levels of estrogen and progesterone hormone receptors (HR), remain an uncertain category, being considered either as triple negative (TN) breast cancers or HR-positive (HR+) tumors across guidelines or approvals. METHODS: ESME is a National real-world …

fr, us (code pays fourni par la source)

18F-FDG-PET-guided, pathological complete response-adapted chemotherapy de-escalation in HER2-positive early breast cancer: 5-year outcomes and exploratory ctDNA analyses from the randomized phase 2 PHERGain trial

Antonio Llombart‐Cussac, José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego et autres

es, ch, fr, gb, be, de, it, pt, us (code pays fourni par la source)

Gestion de la toxicité des conjugués médicaments-anticorps

Florence Dalenc

Les conjugués médicaments-anticorps (ADC) constituent une classe thérapeutique en pleine expansion pour les cancers du sein métastatiques (CSM) RH+ et HER2-. Leur structure permet en théorie d’améliorer l’index thérapeutique. Toutefois, ils ne sont pas dénués d’effets indésirables (EI), potentiellement graves qu’il faut …

Abstract CT275: ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586)

Alexandre Tassin de Nonneville, Jean‐Marie Boher, Jean‐Sébastien Frenel, Gérald Bagoe et autres

Abstract Background: HER2-low metastatic triple-negative breast cancer (mTNBC) is an aggressive disease with limited treatment options. Two antibody-drug conjugates (ADCs), sacituzumab-govitecan (SG) and trastuzumab-deruxtecan (T-DXd), have individually shown superior efficacy versus chemotherapy in advanced settings. Resistance to ADCs, however, frequently emerges due …

fr, lu (code pays fourni par la source)

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence

Chiea Chuen Khor, Whee Sze Ong, Elaine Hsuen Lim, Étienne Chatelut et autres

Tamoxifen's pharmacokinetics are strongly influenced by the highly polymorphic CYP2D6, while the influence of other genetic variants has been inconclusive. To further delineate this genotypic-phenotypic impact, we conducted a multi-ancestry genome-wide association study in 636 hormone-receptor-positive (HR+) breast cancer (BC) patients treated …

sg, fr, de, gb, lb, at (code pays fourni par la source)

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

Chiea Chuen Khor, Whee Sze Ong, Elaine Hsuen Lim, Étienne Chatelut et autres